title: Allosteric modulation of GABA(A) receptor subtypes:effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected].
abstract: Non-selective positive allosteric modulators (PAMs) of GABAA receptors (GABAARs) are known to impair anterograde memory. The role of the various GABAAR subtypes in the memory-impairing effects of non-selective GABAAR PAMs has not been fully elucidated. The current study assessed, in rhesus monkeys, effects of modulation of α1, α2/3, and α5GABAARs on visual recognition and spatial working memory using delayed matching-to-sample (DMTS) and self-ordered spatial search (SOSS) procedures, respectively. The DMTS procedure (n=8) involved selecting a previously presented 'sample' image from a set of multiple images presented after a delay. The SOSS procedure (n=6) involved touching a number of boxes without repeats. The non-selective GABAAR PAM triazolam and the α1GABAA preferential PAMS zolpidem and zaleplon reduced accuracy in both procedures, whereas the α5GABAA preferential PAMs SH-053-2'F-R-CH3 and SH-053-2'F-S-CH3, and the α2/3GABAA preferential PAM TPA023B were without effects on accuracy or trial completion. The low-efficacy α5GABAAR negative allosteric modulator (NAM) PWZ-029 slightly increased only DMTS accuracy, whereas the high-efficacy α5GABAAR NAMs RY-23 and RY-24 did not affect accuracy under either procedure. Finally, the slopes of the accuracy dose-effect curves for triazolam, zolpidem, and zaleplon increased with box number in the SOSS procedure, but were equivalent across DMTS delays. The present results suggest that (1) α1GABAARs, compared with α2/3 and α5GABAARs, are primarily involved in the impairment, by non-selective GABAAR PAMs, of visual recognition and visuospatial working memory in nonhuman primates; and (2) relative cognitive impairment produced by positive modulation of GABAARs increases with number of locations to be remembered, but not with the delay for remembering.
authors.affiliation: Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
authors.forename: Paul L
authors.initials: PL
authors.lastname: Soto
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Ator
authors.forename: Sundari K
authors.initials: SK
authors.lastname: Rallapalli
authors.forename: Poonam
authors.initials: P
authors.lastname: Biawat
authors.forename: Terry
authors.initials: T
authors.lastname: Clayton
authors.forename: James M
authors.initials: JM
authors.lastname: Cook
authors.forename: Michael R
authors.initials: MR
authors.lastname: Weed
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000494:Allosteric Regulation; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects; D003975:Diazepam / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000494:pharmacology; D008253:Macaca mulatta; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D011724:Pyridazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000737:chemistry / Q000145:classification* / Q000378:metabolism*; D021641:Recognition, Psychology / Q000187:drug effects*; D014229:Triazolam / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D000077334:Zolpidem
chemical_list: C507018:7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine; D000081:Acetamides; D007093:Imidazoles; C531941:PWZ-029; D011724:Pyridazines; D011725:Pyridines; D011743:Pyrimidines; C506802:RY 023; C464899:RY 024; D011963:Receptors, GABA-A; C571869:SH-053-2'F-R-CH3; D014230:Triazoles; D001569:Benzodiazepines; D014229:Triazolam; D000077334:Zolpidem; D003975:Diazepam; C085665:zaleplon